Phaseline

Targets › DKK1

DKK1 (Dickkopf-related protein 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology.

Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. (UniProt, O94907)

Open in Phaseline: the race on DKK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Royal Marsden NHS Foundation TrustDKN-01
Dickkopf-related protein 1 inhibitor
DKK1Phase 1Metastatic Esophageal Cancer–

Conditions

Metastatic Esophageal Cancer (1)

Modalities

antibody (1)

Companies

Royal Marsden NHS Foundation Trust (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.